The IL-8 , VEGF , and CFH Polymorphisms and Bevacizumab in Age-related Macular Degeneration

Saved in:
Bibliographic Details
Published inOphthalmology (Rochester, Minn.) Vol. 121; no. 4; pp. 973 - 974.e2
Main Authors Hautamäki, Asta, MD, Kivioja, Jarno, MSc, Seitsonen, Sanna, MD, PhD, Savolainen, Eeva-Riitta, MD, PhD, Liinamaa, M. Johanna, MD, PhD, Luoma, Arto, PhD, Järvelä, Irma, MD, PhD, Immonen, Ilkka, MD, PhD
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.2014
Subjects
Aged
Aged, 80 and over
Angiogenesis Inhibitors - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Bevacizumab
Coloring Agents
Complement Factor H - genetics
Female
Fluorescein Angiography
Genotype
Humans
Indocyanine Green
Interleukin-8 - genetics
Male
Middle Aged
Ophthalmology
Polymorphism, Single Nucleotide
Prospective Studies
Tomography, Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A - genetics
Visual Acuity
Wet Macular Degeneration - diagnosis
Wet Macular Degeneration - drug therapy
Wet Macular Degeneration - genetics
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0161-6420
1549-4713
DOI:10.1016/j.ophtha.2013.11.035